Overview
ISO 9491-1:2026 is an international standard developed by ISO’s Technical Committee on Biotechnology, focusing on the design, development, and implementation of predictive computational models specifically for research in personalized medicine. This standard provides requirements and recommendations to ensure computational models are effectively constructed, verified, and validated for use in health-related research and health product development.
Importantly, ISO 9491-1:2026 addresses the entire model lifecycle-from set-up and formatting to simulation, storing, and sharing-ensuring research processes are transparent, data-driven, and aligned with best practices for interoperability and data provenance. While models used in routine clinical, diagnostic, or therapeutic settings fall outside its scope, the standard is pivotal for research and development environments where innovation and reproducibility are crucial.
Key Topics
- Predictive Computational Models: Guidance on building and curating in silico models for personalized medicine, including mathematical, data-driven, and AI-based approaches.
- Data Requirements: Specification of data formatting, description, annotation, integration, and access protocols. Emphasis is placed on the importance of high-quality, interoperable data for robust model development.
- Model Validation and Verification: Recommendations for calibrating, validating, and verifying models using independent and quality-controlled datasets to ensure accuracy and reproducibility.
- Simulation and Sharing: Requirements for documenting simulation set-ups, capturing results, and sharing model outputs within the research community.
- Data Provenance and Metadata: Ensuring traceability and reliability through robust documentation of data sources, processing, and ownership.
- Ethical Considerations: Outlining ethical requirements-such as privacy and data protection-in computational modelling for personalized medicine.
Applications
ISO 9491-1:2026 is especially valuable for organizations and researchers involved in:
- Personalized Medicine Research: Facilitating translational research where computational models are used to predict disease risk, therapeutic responses, and disease progression.
- Biotechnology and Pharmaceutical Development: Supporting the simulation and validation of new health products or interventions through standardized model building and data integration.
- Clinical Trials: Enhancing the design and execution of in silico clinical trials by providing a framework for virtual patient simulations, pharmacokinetic/dynamic modelling, and quantitative systems pharmacology.
- Collaborative Projects and Research Consortia: Improving data exchange, model reusability, and comparability between institutions and research teams through harmonized standards.
- AI and Machine Learning in Healthcare: Establishing guidelines for the use of data-driven models, including artificial intelligence and machine learning systems, with a focus on model quality, transparency, and result reproducibility.
Related Standards
ISO 9491-1:2026 aligns with and references several other international standards crucial for data management and modelling in biotechnology, including:
- ISO 20691: Biotechnology - Requirements for data formatting and description in the life sciences
- ISO 20387:2026: Biotechnology - Biobanking - General requirements for biobanks
- ISO 23494-1: Provenance information model for biological material and data - Part 1: Design concepts and general requirements
- ISO 23494-2: Common Provenance Model
These standards collectively support the FAIR (Findable, Accessible, Interoperable, Reusable) and ALCOA (Attributable, Legible, Contemporaneous, Original, Accurate) principles integral to data and model management in biomedical research.
Practical Value
Implementing ISO 9491-1:2026 enables:
- Enhanced Reproducibility: By standardizing processes, models, and data, research outcomes become easier to reproduce and validate across the global scientific community.
- Greater Data Interoperability: Reducing heterogeneity and fostering integration of disparate health data sources.
- Improved Collaboration: Supporting multi-site studies and data sharing while safeguarding data integrity and provenance.
- Robust Model Development for R&D: Accelerating the advancement of innovative therapies and personalized medicine approaches through validated and reliable predictive models.
By integrating the requirements and recommendations of ISO 9491-1:2026, organizations and researchers position themselves at the forefront of standardized, impactful biomedical innovation.